Trial Profile
A phase II randomized controlled trial evaluating the immunogenicity and safety of a recombinant aP vaccine and various Tdap vaccine formulations in healthy women of child bearing age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary) ; Pertussis acellular vaccine (Primary) ; DTaP vaccine
- Indications Pertussis
- Focus Pharmacodynamics
- Sponsors BioNet-Asia
- 06 Dec 2021 Results published in the BioNet-Asia Media Release.
- 14 Nov 2021 Results published in the Vaccine
- 11 Sep 2018 Status changed from recruiting to completed.